| 0.3009 -0.014 (-4.42%) | 09-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.41  |
1-year : | 0.46 |
| Resists | First : | 0.35 |
Second : | 0.39 |
| Pivot price | 0.32 |
|||
| Supports | First : | 0.29 |
Second : | 0.24 |
| MAs | MA(5) : | 0.3 |
MA(20) : | 0.32 |
| MA(100) : | 0.38 |
MA(250) : | 0.59 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 19.2 |
D(3) : | 20 |
| RSI | RSI(14): 38.1 |
|||
| 52-week | High : | 1.25 | Low : | 0.23 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MOVE ] has closed above bottom band by 22.8%. Bollinger Bands are 36.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.31 - 0.31 | 0.31 - 0.31 |
| Low: | 0.3 - 0.3 | 0.3 - 0.3 |
| Close: | 0.3 - 0.3 | 0.3 - 0.3 |
Movano Inc. engages in developing a platform to deliver healthcare solutions at the intersection of medtech and consumer devices. Its platform uses radiofrequency technology, which enables the creation of sensors that are small enough to fit into wearable devices and other small form factors. The company develops Movano Ring that measures heart rate, heart rate variability, sleep, respiration, temperature, blood oxygen saturation, steps, and calories, as well as incorporates women-centric features and design. It is also developing non-invasive continuous glucose monitoring and cuffless blood pressure monitoring features to its technology platform. The company was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. Movano Inc. was incorporated in 2018 and is based in Pleasanton, California.
Tue, 03 Sep 2024
Movano Health Advances to Final Phase of FDA Review Process for EvieMED Ring - StockTitan
Wed, 14 Aug 2024
Movano Health Reports Q2 2024 Financial Results and Provides Business Update - StockTitan
Wed, 14 Aug 2024
Movano Health Reports Q2 2024 Financial Results and Provides Business Update - PR Newswire
Mon, 05 Aug 2024
Movano Health Provides Progress Update on EvieMED Regulatory Filing - StockTitan
Mon, 05 Aug 2024
Movano Health to Report Second Quarter 2024 Financial Results on Wednesday August 14, 2024 - StockTitan
Tue, 30 Jul 2024
Movano Evie Ring Could Soon Get FDA Clearance, Analyst Says: 'A Validated Wearable Device Truly Opens The Market' - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 99 (M) |
| Held by Insiders | 7.617e+007 (%) |
| Held by Institutions | 17.3 (%) |
| Shares Short | 367 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.709e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 198.8 % |
| Return on Equity (ttm) | -88.8 % |
| Qtrly Rev. Growth | 852000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -1510.42 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.21 |
| Dividend | 0 |
| Forward Dividend | 383550 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|